Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Lymphoma, Follicular 5Lymphoma, Mantle-Cell 4Leukemia, Lymphocytic, Chronic, B-Cell 4Lymphoma, B-Cell, Marginal Zone 3Lymphoma, B-Cell 2Hodgkin Disease 2Waldenstrom Macroglobulinemia 1Primary Myelofibrosis 1Polycythemia Vera 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Disease Progression 1

Interventions

fludarabine phosphate 24Peripheral Blood Stem Cell Transplantation 21Cyclophosphamide 21Busulfan 19Whole-Body Irradiation 15Tacrolimus 15Mycophenolic Acid 13Methotrexate 12ruxolitinib 11Cyclosporine 10Antilymphocyte Serum 10fludarabine 8Melphalan 7peginterferon alfa-2a 6Aspirin 6Filgrastim 5Stem Cell Transplantation 4Radiotherapy 4Imatinib Mesylate 4Hydroxyurea 4Flow Cytometry 4Etoposide 4Decitabine 4Biopsy 4Azacitidine 4Thiotepa 3Surveys and Questionnaires 3Prednisone 3Methylprednisolone 3Injections 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Polycythemia Vera × umbralisib × Clear all
NCT02493530 2026-05-19

TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea

Vanderbilt-Ingram Cancer Center

Phase 1 Completed
60 enrolled
Myeloid

Polycythemia Vera, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡